Industry News
Biotechnology Industry News
Dianthus to follow ‘north star’ on mission to reduce autoimmune injections with $100M funding
Dianthus to follow 'north star' on mission to reduce autoimmune injections with $100M funding jwaldron Tue, 05/03/2022 - 08:19
Tackling toxicity, Tubulis lands $63M to advance ADC pipeline spearheaded by Adcetris rival
Tackling toxicity, Tubulis lands $63M to advance ADC pipeline spearheaded by Adcetris rival ntaylor Tue, 05/03/2022 - 03:10
As expected, FDA spikes down Axsome migraine med, but issues are ‘addressable’
As expected, FDA spikes down Axsome migraine med, but issues are 'addressable' mbayer Mon, 05/02/2022 - 16:25
All Takeda wants for its billion-dollar gene therapy spending spree is functional cures
All Takeda wants for its billion-dollar gene therapy spending spree is functional cures aarmstrong Mon, 05/02/2022 - 15:36
Biogen takes another dip into Scribe gene therapy collab with another disease target
Biogen takes another dip into Scribe gene therapy collab with another disease target mbayer Mon, 05/02/2022 - 13:30
Patient Square Capital invests $300M to support ‘golden age of therapeutics’ with Enavate Sciences
Patient Square Capital invests $300M to support 'golden age of therapeutics' with Enavate Sciences gmasson Mon, 05/02/2022 - 11:52
Unwelcome surprise for Vertex as FDA slaps hold on phase 1/2 diabetes cell therapy study
Unwelcome surprise for Vertex as FDA slaps hold on phase 1/2 diabetes cell therapy study aarmstrong Mon, 05/02/2022 - 10:23
Eyelid mites no match for Tarsus eye drop, as phase 3 data spurs drive to FDA
Eyelid mites no match for Tarsus eye drop, as phase 3 data spurs drive to FDA mbayer Mon, 05/02/2022 - 10:16
Eyelid mites no match for Tarsus eye drop, as phase 3 data spur drive to FDA
Eyelid mites no match for Tarsus eye drop, as phase 3 data spur drive to FDA mbayer Mon, 05/02/2022 - 10:16
Sage, Biogen get rolling on FDA submission for depression med
Sage, Biogen get rolling on FDA submission for depression med aarmstrong Mon, 05/02/2022 - 09:46
Gilead follows Big Pharma peers to Dragonfly’s pond in $300M deal for natural killer cell engagers
Gilead follows Big Pharma peers to Dragonfly's pond in $300M deal for natural killer cell engagers aarmstrong Mon, 05/02/2022 - 09:10
Stealth stumbles again as age-related macular degeneration joins list of clinical trial flops
Stealth stumbles again as age-related macular degeneration joins list of clinical trial flops ntaylor Mon, 05/02/2022 - 08:53
After posting midphase data, Rezolute banks $130M to take treatment for rare disease into pivotal trial
After posting midphase data, Rezolute banks $130M to take treatment for rare disease into pivotal trial ntaylor Mon, 05/02/2022 - 07:40
Seeing green: Breakthrough Properties raises $3B to build in biotech
Seeing green: Breakthrough Properties raises $3B to build in biotech gmasson Fri, 04/29/2022 - 16:19
Human testing for Praxis’ lead epilepsy drug held up after FDA clinical hold
Human testing for Praxis' lead epilepsy drug held up after FDA clinical hold gmasson Fri, 04/29/2022 - 12:11
AstraZeneca will have to wait a little longer for fruit from $3.5B Ionis ATTR partnership
AstraZeneca will have to wait a little longer for fruit from $3.5B Ionis ATTR partnership aarmstrong Fri, 04/29/2022 - 12:04
AbbVie’s cystic fibrosis long-game doesn’t pay off, as Galapagos med fails in triple combo
AbbVie's cystic fibrosis long-game doesn't pay off, as Galapagos med fails in triple combo aarmstrong Fri, 04/29/2022 - 11:02
While BMS waits for TYK2 inhibitor’s psoriasis nod, a new path potentially clears in lupus
While BMS waits for TYK2 inhibitor’s psoriasis nod, a new path potentially clears in lupus mbayer Fri, 04/29/2022 - 10:29
Genocea’s Atlas no longer holding up sky, as biotech moves for sell off
Genocea's Atlas no longer holding up sky, as biotech moves for sell off aarmstrong Fri, 04/29/2022 - 10:00
Finch’s C. diff drug cleared of FDA hold, but loose ends leave timing for phase 3 restart unclear
Finch's C. diff drug cleared of FDA hold, but loose ends leave timing for phase 3 restart unclear aarmstrong Fri, 04/29/2022 - 08:46